{
    "id": 383,
    "fullName": "MYCN amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MYCN amp indicates an increased number of copies of the MYCN gene. However, the mechanism causing the increase has not been specified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4613,
        "geneSymbol": "MYCN",
        "terms": [
            "MYCN",
            "bHLHe37",
            "MODED",
            "N-myc",
            "NMYC",
            "ODED"
        ]
    },
    "variant": "amp",
    "createDate": "03/13/2014",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2992,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-63 inhibited growth of neuroblastoma cell lines harboring MYCN amplification (PMID: 21725357).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1582,
                "therapyName": "MI-63",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3556,
                    "pubMedId": 21725357,
                    "title": "MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5890,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplified neuroblastoma cells were sensitive to Venclexta (venetoclax) in culture, resulting in inhibition of cell growth (PMID: 26859456).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5184,
                    "pubMedId": 26859456,
                    "title": "Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26859456"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10862,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring MYCN amplification demonstrated decreased cell viability and cell proliferation, and increased apoptotic activity when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5892,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplified neuroblastoma cells were sensitive to the combination of Venclexta (venetoclax) and Alisertib (MLN8237) in both culture and cell line xenograft models, as well as a patient derived xenograft (PDX) model of neuroblastoma, resulting in high levels of apoptosis, cell growth arrest, and tumor regression (PMID: 26859456).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 3972,
                "therapyName": "Alisertib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5184,
                    "pubMedId": 26859456,
                    "title": "Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26859456"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4991,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cells with MYCN amplification demonstrated decreased sensitivity to treatment with GANT61 in culture compared to cells without MYCN amplification (PMID: 22949014).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4827,
                    "pubMedId": 22949014,
                    "title": "Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22949014"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1169,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplification was found to be a dominant predictor of JQ1 response as evidenced by increased survival in three different models of MYCN amplified neuroblastoma (PMID: 23430699).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 914,
                    "pubMedId": 23430699,
                    "title": "Targeting MYCN in neuroblastoma by BET bromodomain inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23430699"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2804,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PW12 inhibited growth of MYCN-amplified neuroblastoma cells in culture and reduced tumor growth in mouse models of MYCN-amplified neuroblastoma (PMID: 26029667).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2961,
                "therapyName": "PW12",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3486,
                    "pubMedId": 26029667,
                    "title": "Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26029667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10870,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma cell line harboring MYCN amplification demonstrated reduced cell viability when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2991,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, nutlin-3 inhibited growth of neuroblastoma cell lines harboring MYCN amplification (PMID: 21725357).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3556,
                    "pubMedId": 21725357,
                    "title": "MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3638,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT7519 inhibited growth of human neuroblastoma cell lines harboring MYCN amplification in culture, and blocked tumor progression in MYCN-amplified patient-derived xenograft models (PMID: 26202950).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3922,
                    "pubMedId": 26202950,
                    "title": "Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1168,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CD532 inhibited cell growth of a wide panel of tumor cell lines in vitro, with MYCN-amplified lines significantly more susceptible than nonamplified lines (PMID: 25175806).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1628,
                "therapyName": "CD532",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 913,
                    "pubMedId": 25175806,
                    "title": "Drugging MYCN through an allosteric transition in Aurora kinase A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25175806"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1167,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CD532 inhibited cell growth of MYCN-amplified medulloblastoma cell lines significantly more than nonamplified lines (PMID: 25175806).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1628,
                "therapyName": "CD532",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 913,
                    "pubMedId": 25175806,
                    "title": "Drugging MYCN through an allosteric transition in Aurora kinase A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25175806"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 10058-F4 induced apoptosis and inhibited growth of MYCN-amplified neuroblastoma cell lines in culture (PMID: 24859015).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 3304,
                "therapyName": "10058-F4",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6446,
                    "pubMedId": 24859015,
                    "title": "Targeting of the MYCN protein with small molecule c-MYC inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24859015"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1170,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT137690 inhibited MYCN amplified neuroblastoma cell lines in vitro more potently than non MYCN amplified lines and inhibited tumor growth in a MYCN-driven transgenic mouse model of neuroblastoma (PMID: 21885865).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1629,
                "therapyName": "CCT137690",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 916,
                    "pubMedId": 21885865,
                    "title": "The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21885865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1736,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NVP-CGM097 and Zykadia (NVP-LDK378) decreased MYCN protein in MYCN-amplified human neuroblastoma cell lines in culture and induced tumor regression in cell line xenograft models (Cancer Res 2014; 74 (19 Suppl); Abstract nr 2929).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2148,
                "therapyName": "Ceritinib + CGM097",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1982,
                    "pubMedId": null,
                    "title": "The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/2929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10861,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring MYCN amplification demonstrated decreased cell viability and cell proliferation, and increased apoptotic activity when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1745,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovitine (Seliciclib) significantly decreased MYCN expression in neuroblastoma cell lines harboring MYCN amplifications (PMID: 24317512).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1995,
                    "pubMedId": 24317512,
                    "title": "CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24317512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10871,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma cell line harboring MYCN amplification demonstrated reduced cell viability when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5609,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, THZ1 inhibited proliferation of MYCN-amplified neuroblastoma cell lines in culture and suppressed tumor growth in MYCN-amplified neuroblastoma cell line xenograft models (PMID: 25416950).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 3908,
                "therapyName": "THZ1",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5125,
                    "pubMedId": 25416950,
                    "title": "CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25416950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5889,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplified neuroblastoma cells were sensitive to Navitoclax (ABT-263) in culture, resulting in inhibition of cell growth (PMID: 26859456).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 825,
                "therapyName": "Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5184,
                    "pubMedId": 26859456,
                    "title": "Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26859456"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5893,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN amplified neuroblastoma cells were sensitive to the combination of Venclexta (venetoclax) and Tozasertib (VX-680) in culture, resulting in high levels of apoptosis and cell growth arrest (PMID: 26859456).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 3973,
                "therapyName": "Tozasertib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5184,
                    "pubMedId": 26859456,
                    "title": "Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26859456"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1166,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CD532 inhibited cell growth of MYCN-amplified neuroblastoma cell lines significantly more than nonamplified lines (PMID: 25175806).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 1628,
                "therapyName": "CD532",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 913,
                    "pubMedId": 25175806,
                    "title": "Drugging MYCN through an allosteric transition in Aurora kinase A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25175806"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7157,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with the combination of Alisertib (MLN8237), Camptosar (irinotecan), and Temodar (temozolomide) demonstrated safety and resulted in an overall response rate of 31.8%, with a response rate of 35.7% in patients with MYCN-nonamplified tumors, and 16.7% in patients with MYCN amplification (PMID: 26884555).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2628,
                "therapyName": "Alisertib + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5102,
                    "pubMedId": 26884555,
                    "title": "Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884555"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15481,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Alisertib (MLN8237), Camptosar (irinotecan), and Temodar (temozolomide) resulted in decreased 1-year progression-free survival rate (10% vs 47%, p=0.018) in neuroblastoma patients with MYCN amplification compared to patients without MYCN amplification (PMID: 30093449; NCT01601535).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2628,
                "therapyName": "Alisertib + Irinotecan + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13334,
                    "pubMedId": 30093449,
                    "title": "Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093449"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8328,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCN-amplified neuroblastoma cell lines demonstrated increased sensitivity to Birabresib (OTX015) compared to non-amplified cell lines in culture and in cell line xenograft models (PMID: 26631615).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6614,
                    "pubMedId": 26631615,
                    "title": "Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26631615"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6586,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 and Farydak (panobinostat) worked synergistically to induce apoptosis and alter expression of target genes in MYCN-amplified human neuroblastoma cell lines in culture and to reduce Mycn expression and decrease tumor growth in MYCN-amplified neuroblastoma xenograft models (PMID: 26733615).",
            "molecularProfile": {
                "id": 478,
                "profileName": "MYCN amp"
            },
            "therapy": {
                "id": 4185,
                "therapyName": "JQ1 + Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5706,
                    "pubMedId": 26733615,
                    "title": "The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733615"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1416,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kisqali (ribociclib) demonstrated sensitivity in a set of neuroblastoma cell lines and xenograft models, which express CDK4/6 and display active CDK4/6 signalling, and harbor amplification of MYCN (PMID: 24045179).",
            "molecularProfile": {
                "id": 2488,
                "profileName": "CDK6 pos MYCN amp"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 828,
                    "pubMedId": 24045179,
                    "title": "Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24045179"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1451,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kisqali (ribociclib) demonstrated sensitivity in a set of neuroblastoma cell lines and xenograft models, which express CDK4/6 and displays active CDK4/6 signalling, and harbor amplification of MYCN (PMID: 24045179).",
            "molecularProfile": {
                "id": 2528,
                "profileName": "CDK4 pos MYCN amp"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 828,
                    "pubMedId": 24045179,
                    "title": "Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24045179"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16058,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with metastatic castration-resistant prostate adenocarcinoma with neuroendocrine differentiation harboring AURKA and MYCN amplification, and an MSH6 mutation, remained on Alisertib (MLN8237) therapy for over 3 years with no evidence of disease progression (PMID: 30232224; NCT30232224).",
            "molecularProfile": {
                "id": 31393,
                "profileName": "AURKA amp MSH6 mut MYCN amp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 2526,
                "name": "prostate adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14171,
                    "pubMedId": 30232224,
                    "title": "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 478,
            "profileName": "MYCN amp",
            "profileTreatmentApproaches": [
                {
                    "id": 6462,
                    "name": "PW12",
                    "profileName": "MYCN amp"
                },
                {
                    "id": 7225,
                    "name": "AT7519",
                    "profileName": "MYCN amp"
                },
                {
                    "id": 152,
                    "name": "AURK Inhibitor (Pan)",
                    "profileName": "MYCN amp"
                },
                {
                    "id": 6461,
                    "name": "BEZ235",
                    "profileName": "MYCN amp"
                },
                {
                    "id": 151,
                    "name": "Aurka Inhibitors",
                    "profileName": "MYCN amp"
                },
                {
                    "id": 4010,
                    "name": "BET  Inhibitor (Pan)",
                    "profileName": "MYCN amp"
                }
            ]
        },
        {
            "id": 2488,
            "profileName": "CDK6 pos MYCN amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2528,
            "profileName": "CDK4 pos MYCN amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31392,
            "profileName": "AURKA amp MYCN amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31393,
            "profileName": "AURKA amp MSH6 mut MYCN amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}